Updates on immunotherapy in non-small cell lung cancer

Bibliography

• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Carcereny E, et al. Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clin Transl Oncol 2010;12:75-80
   PubMed Web of Science ®Google Scholar
• Shablak A, Sikand K, Shanks JH, et al. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother 2011;34:107-12
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Cassidy PB, Leachmann S, et al. Novel approaches in melanoma prevention and therapy. Cancer Treat Res 2014;159:443-55
   PubMedGoogle Scholar
• Shimizu K, Nakata M, Hirami Y, et al. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010;5:585-90
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Sethi N, Ahmed N. Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol Ther 2012;12:923-37
   PubMed Web of Science ®Google Scholar
• Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014;11:24-37
   PubMed Web of Science ®Google Scholar
• Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008;26:1452-8
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov. A randomized trial to study the safety and efficacy of EGF cancer vaccination in late-stage (IIIB/IV) non-small cell lung cancer patients (NSCLC). Available from: ClinicalTrial.gov [Last accessed 20 November 2013]
   Google Scholar
• Sistigu A, Viaud S, Chaput N, et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011;33:369-83
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(1):59-68
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Liposome vaccine and bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery. Available from: http://clinicaltrials.gov/ [Last accessed 20 November 2013]
   Google Scholar
• ClinicalTrials.gov. Phase IIB/III Of TG4010 immunotherapy in patients with stage IV non-small cell lung cancer (TIME). Available from: clinicaltrials.gov [Last accessed 20 November 2013]
   Google Scholar
• The Oncology Report. Vaccine extended overall survival in subset of NSCLC patients. Available from: http://www.oncologypractice.com/index.php?id=5740&cHash=071010&tx_ttnews%5Btt_news%5D=218169 [Last accessed 20 November 2013]
   Google Scholar
• Shimanovsky A, Jethava A, Dasanu CA. Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opin Biol Ther 2013;13:1413-27
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24:75-83
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Trial in squamous non small cell lung cancer subjects comparing ipilimumab plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin. Available from: http://clinicaltrials.gov [Last accessed 20 November 2013]
   Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800
   PubMed Web of Science ®Google Scholar
• Probst HC, McCoy K, Okazaki T, et al. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005;6:280-6
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Horn L, Antonia SJ, et al. Nivolumab(Anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in phase I trial. In Journal of Thoracic Oncology. 2013. vol 8, Supplement 2.] (Abst: M018.03). Available from: http://www.2013worldlungcancer.org/documents/WCLC2013-AbstractBook.pdf
   Google Scholar
• Rizvi N, Antonina JS, Chow LQ, et al. A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013;31(Suppl):abstract 8072
   Google Scholar
• ClinicalTrial.gov. Study of BMS-936558 (Nivolumab) compared to docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) (CheckMate 017). Available from: http://clinicaltrial.gov [Last accessed 20 November 2013]
   Google Scholar
• Garon EB, Balmanoukian A, Hamid O, et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC) International Association for the Study of Lung Cancer. (Abst: M018.02). Available from: http://abstracts.webges.com/myitinerary/session-116.html?congress=wclc2013
   Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
   PubMed Web of Science ®Google Scholar
• Soria JC, Cruz C, Bahleda R, et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). The European Cancer Congress 2013. (Abst: 3408). Available from: http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx?abstractid=6899
   Google Scholar
• Spigel DR, Gettinger SN, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic Non-small cell lung cancer (NSCLC). J Clin Oncol 2013;31(Suppl):abstract 8008
   Google Scholar